AlloVir downgraded by Leerink Partners
$ALVR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Leerink Partners downgraded AlloVir from Outperform to Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/26/2023 | $17.00 → $1.00 | Buy → Underperform | BofA Securities |
| 12/22/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/22/2023 | Overweight → Underweight | JP Morgan | |
| 12/22/2023 | Overweight → Neutral | Piper Sandler | |
| 8/18/2023 | $17.00 | Buy | BofA Securities |
| 2/10/2022 | $32.00 → $30.00 | Outperform | SVB Leerink |
| 1/18/2022 | $48.00 → $45.00 | Overweight | Morgan Stanley |
| 12/17/2021 | $37.00 → $32.00 | Outperform | SVB Leerink |
BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously
Leerink Partners downgraded AlloVir from Outperform to Market Perform
JP Morgan downgraded AlloVir from Overweight to Underweight
SC 13G - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
- Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology
144 - Allovir, Inc. (0001754068) (Subject)
144 - Allovir, Inc. (0001754068) (Subject)
144 - Allovir, Inc. (0001754068) (Subject)
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. iBio, Inc. (NYSE:IBIO) On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company’s stock fell around 11% over the
The move follows AlloVir’s announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. raised Karuna Therapeutics, Inc. (NASDAQ:KRTX) price target from $300 to $330. HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the stock from Buy to Neutral. Karuna Therapeutics shares jumped 47.7% to close at $317.85 on Friday. See how other analysts view this stock. B of A Securities cut the price target for AlloVir, Inc. (NASDAQ:ALVR) from $17 to $1. B of A Securities analyst Jason Zemansky downgraded the stock from Buy to Underperform. AlloVir shares fell 67.2% to
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)